US 6,649,166 B1 · Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same

Abstract

The invention concerns peptides and proteins for desensitizing specifically the vast majority of subjects allergic to bee venom and compositions containing said peptides or proteins. The peptides are selected in the group consisting of: the fragment (1) corresponding to positions P85-97 of the major bee venom allergen, the fragment (2) corresponding to positions P81-93 of the major bee venom allergen, the fragment (3) corresponding to positions P94-106 of the major bee venom allergen, the fragment (4) corresponding to positions P76-88 of the major bee venom allergen, the fragment (5) corresponding to positions P77-94 of the major bee venom allergen, and the fragment (6) corresponding to positions P122-134 of the major bee venom allergen, fragments (I) and (2) forming group (1); fragment (3) forming group (II); fragments (4) and (4) forming group (III) and fragment (6) forming group IV and the mutated fragments of said fragments (1) to (6) which have a binding activity with MHC class (II) molecules identical or higher than those of said fragments (1) to (6). The invention also concerns compositions containing said peptides or proteins.

Claims13

Dependent claims

A polypeptide molecule capable of desensitizing a human subject to bee venom, the polypeptide selected from the group consisting of:

(a) a polypeptide molecule corresponding to amino acid positions 85-97 of SEQ ID NO:
8;
(b) a polypeptide molecule corresponding to amino acid positions 81-93 of SEQ ID NO:
8;
(c) a polypeptide molecule corresponding to amino acid positions 94-106 of SEQ ID NO:
8;
(d) a polypeptide molecule corresponding to amino acid positions 76-88 of SEQ ID NO:
8;
(e) a polypeptide molecule corresponding to amino acid positions 77-94 of SEQ ID NO:
8;
(f) a polypeptide molecule corresponding to amino acid positions 122-134 of SEQ ID NO:
8;
and (g) a polypeptide molecule of (a)-(f) comprising at least one amino acid substitution, wherein the substituted polypeptide exhibits binding activity to MHC class II molecules identical to or greater than that of the polypeptides (a)-(f).

10 more elements

A pharmaceutical composition for desensitizing a human subject to bee venom comprising:

(a) at least one polypeptide molecule corresponding to amino acid positions 85-97 of SEQ ID NO:
8 or to amino acid positions 81-93 of SEQ ID NO:
8;
(b) at least one polypeptide molecule of at least 13 amino acids and corresponding to a consecutive amino acid sequence within the range of amino acid positions 81-97 of SEQ ID NO:
8 and which binds to at least one HLA-DR molecule encoded by the HLA alleles DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 or DRB1*1501 with a binding activity <1000 nM;
(c) at least one polypeptide molecule corresponding to amino acid positions 94-106 of SEQ ID NO:
8 or a polymer thereof;
(d) at least one polypeptide molecule of at least 13 amino acids and corresponding to a consecutive amino acid sequence within the range of amino acid positions 94-106 of SEQ ID NO:
8, the molecule binding to at least one HLA-DR molecule encoded by the alleles DRB1*0101, DRB1*0401 or DRB1*1101 with a binding activity <1000 nM;
(e) at least one polypeptide molecule corresponding to amino acid positions 76-88 or 77-94 of SEQ ID NO:
8 or a polymer thereof;
(f) at least one polypeptide molecule of at least 13 amino acids and corresponding to a consecutive amino acid sequence within the range of amino acid positions 76-94 of SEQ ID NO:
8, the molecule binding to at least one HLA-DR molecule encoded by the alleles DRB1*0701, DRB1*1101 or DRB1*1501 with a binding activity <1000 nM;
(g) at least one polypeptide molecule corresponding to amino acid positions 122-134 of SEQ ID NO:
8 or a polymer thereof;
(h) at least one polypeptide molecule of at least 13 amino acids and corresponding to a consecutive amino acid sequence within the range of amino acid positions 122-134 of SEQ ID NO:
8, the molecule binding to at least one HLA-DR molecule encoded by the alleles DRB1*1101, DRB1*1301 or DRB1*1501 with a binding activity <1000 nM;
and
(i) at least one pharmaceutically acceptable vehicle,
wherein any polypeptide may contain at least one mutation such that the resultant mutant binds at least to one HLA-DR molecule encoded by the alleles DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 or DRB1*1501 with a binding activity <1000 nM.

17 more elements

Dependencies are inferred from the claim text.

Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same

Life of this patent

Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same

Life of this patent

Abstract

Claims13